Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Q: Paragraph: Samoa declared a national emergency last month and mandated that all 200,000 people living on the South Pacific island nation get vaccinated. The government has closed all schools and banned children from public gatherings. In all, 53 people have died in the outbreak since late October, including one adult and two older teenagers. Most of those who have died have been babies and young infants, including 23 children aged less than 1 and 25 children aged between 1 and 4. The government said more than 1,100 people have been admitted to hospitals since the outbreak began and about 180 people remain hospitalized. Among those hospitalized are 19 children who are in critical condition. Samoan authorities believe the virus was first spread by a traveler from New Zealand. New Zealand Prime Minister Jacinda Ardern said Monday that her country was doing everything it could to help curb the epidemic, including sending more than 50 medical professionals and thousands of vaccines to Samoa. Other countries including Britain have also sent teams and supplies. Ardern said the natural curve of infection rates meant that “sometimes things can be worse before they are better.” Figures from the World Health Organization and UNICEF indicate that fewer than 30% of Samoan infants were immunized last year. That low rate was exacerbated by a medical mishap that killed two babies who were administered a vaccine that had been incorrectly mixed, causing wider delays and distrust in the vaccination program. The government said about 33,000 people were vaccinated before last month and since then, another 58,000 people have been vaccinated. The World Health Organization has set a target of wiping out measles from most of the world by next year. It says the disease is entirely preventable thanks to a safe vaccine that has been in use since the 1960s, and that measles deaths worldwide decreased by 84% between 2000 and 2016 to about 90,000 annually thanks to better immunization. Claim: 50 children killed by measles in Samoa as outbreak worsens.

A: Samoa’s government said Monday that another five children had died within the past day from a measles outbreak, bringing the death toll from the epidemic to more than 50 as authorities race to vaccinate the entire population.
****
Q: Paragraph: No mention of the cost of treatment. This is important if the surgery is not a permanent fix for acute sinusitis. Repeated operations and continued medications need to be compared to cost for traditional surgery. No quantitative estimate of the benefits of the new procedure. There was a study of 10 people that found “no safety concerns”, but readers should be told more about this very small group. What were the long term outcomes and did these patients eventually have to have further sinuplasty, more invasive surgery or continue to take medications to relieve sinusitits? The story mentions that a larger, randomized trial is underway to better understand the risks and benefits of sinuplasty compared to medication and traditional sinus surgery. Mentions that more information is needed and no one knows if balloon sinuplasty works as well as the more traditional surgical option for chronic sinusitis. Mentions that general anesthesia is still needed for balloon procedure and this comes with its own set of health risks. There isn’t much evidence for the story to report. The story did stress the importance of a randomized trial underway comparing medication, traditional sinus surgery and the newer balloon sinuplasty. Story describes this trial and the need for further evidence before this new procedure can be widely recommended. Mentions that this procedure should not have been FDA approved with so little quality evidence. No evidence of disease mongering. The story mentions that this procedure would be for chronic, not acute sinunitis and describes how these are different. Good balance of information on treatment options with input from otolaryngologists not affliated with the makers of the device who are able to provide perspective on the new procedure. They mention that further study is needed. There is a note that one of the physicans studying the new sinuplasty has no financial ties to Acclarent, maker of the balloon devices used in this type of sinuplasty. Mentions that this form of sinuplasty is not for everybody and that it may not prevent the need for more comprehensive surgery in which bone and tissue are removed. There is mention of other options including medication and the more traditional surgery, which is decribed as highly effective, but with a painful recovery and side effects such as scar tissue. Quantification of the incidence of this and other side effects of traditional surgery would be useful. The story is clear that the FDA approved the device but that it still needs to undergo further study via randomized controlled trials. Story mentions that this is a new procedure only offerred by 100 doctors. This story is a blananced presentation of sinuplasty and the information here does not appear to be from a press release. The are quotes from otolaryngologists not affliated with the makers of the device who are able to provide perspective on the new sinuplasty procedure. Claim: A balloon instead of a knife: Sinuplasty for ailing sinuses

A: This story provides a good balance of information on a new treatment option for chronic sinusitis, and there is corroboration with otolaryngologists not affiliated with the makers of the balloon device who are able to provide perspective on the procedure. The story clearly notes this procedure would be for chronic, not acute sinusitis and describes how these are different. The story explains that this form of sinuplasty is not for everybody, and that it may not prevent the need for more comprehensive surgery in which bone and inflamed tissue are removed to open the sinus passages. More information is needed on the safety and efficacy of balloon sinuplasty, and no one knows if this surgery works as well as traditional surgery for chronic sinusitis. The story mentions other options for treating chronic sinusitis, including medication and sinus surgery, which is described as highly effective, but with a painful recovery and side effects such as scar tissue. Quantification of the incidence of side effects with traditional surgery would be useful. While there is not much quantitative evidence available on the new procedure, the story stresses the importance of a randomized trial underway comparing medication, traditional sinus surgery and the newer balloon sinuplasty. There is adequate description of this trial and the need for further evidence before this new procedure can be widely recommended. There is a caveat that this procedure should not have been FDA approved with so little quality evidence: a study of 10 people that found “no safety concerns”, but readers should be told more about this very small group. What were the long term outcomes and did these patients eventually have to undergo further sinuplasty, more invasive surgery or continue to take medications to relieve their chronic sinusitis? The story explains that general anesthesia is still needed for the balloon procedure and this comes with its own set of health risks and additional costs. There is no mention of the cost of this newer procedure. This is important information if the surgery is not a permanent fix for chronic sinusitis. A cost comparison of the newer sinuplasty, which may require repeated operations, sinus medications and traditional surgery is needed.
****
Q: Paragraph: Measles has killed nearly three times as many people in Congo than an Ebola outbreak in the country that has garnered far more international attention, particularly after health teams came under attack from armed militias operating in the area. “Lack of funding remains a huge impediment to successfully curbing the outbreak,” WHO said in announcing its appeal. While $27.6 million already has been mobilized to curb the measles epidemic, WHO said that $40 million is needed for a special six-month plan to vaccinate older children between the ages of 6 and 14. A vaccine against measles has existed for decades but some 310,000 cases have been reported in Congo since the beginning of 2019. Health workers in Congo struggle to access remote parts of the vast country, and vaccination rates remain low in areas where armed groups operate. Many health resources in Congo this year also have been devoted to the simultaneous outbreak of Ebola, which has become the second worst in history after the 2014-2016 West Africa epidemic. At least 2,231 people have died of Ebola since that outbreak was first identified in August 2018. Claim: WHO: Death toll from measles outbreak in Congo hits 6,000.

A:
The death toll from a measles epidemic in Congo has surpassed 6,000, the World Health Organization said Tuesday as it warned that more funds are needed to save lives during the world’s worst outbreak of the infectious disease.
****